long intergenic non-protein coding RNA 1926Genealiases: []
Q-omics provides the consensus-scored LINC01926 profile across patient tissues and cancer cell-line models. LINC01926 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01926 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, LINC01926 RNA expression shows 8,909 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, LUAD, and TGCT as cancer lineages where LINC01926 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01926 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01926 survival associations across molecular data types. LINC01926 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01926 RNA expression–survival associations across cancer types. High LINC01926 expression shows unfavorable associations in LUSC, UVM and KIRC, but favorable associations in SKCM, LUAD and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01926 RNA expression.
This table summarizes LINC01926 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01926. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01926 shows lower tumor expression in KICH and higher tumor expression in LUAD, BRCA, KIRC, HNSC and LUSC. The LUAD box plot shows higher LINC01926 RNA expression in tumor versus normal tissue (log2 FC = +0.301, t-test p < 0.001).
This table shows molecular features associated with LINC01926 in patient tissues and cancer cell lines. In patient samples, LINC01926 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
